F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

Recruiting now · Not applicable

Conditions studied: Thyroid Cancer, Differentiated Thyroid Cancer

In brief

In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity. F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies. The primary aim of this study is to comparatively evaluate the role of F-18 TFB PET/CT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET/CT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy. The secondary aims are to investigate the factors predicting F-18 TFB PET/CT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET/CT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.

Key facts

Study ID

NCT07436455

Run by

Ankara University

People needed

50

Starts

2025-11-01

Expected to finish

2026-10-01

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy
• Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up
• Negative or equivocal I-131 whole-body scan findings
• Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] performance status)
• Giving written informed consent

You may not qualify if…

• Age under 18 years
• Pregnancy or breastfeeding
• Failure to provide written informed consent

Where it is running

• Ankara University Medical School Nuclear Medicine Department — Ankara, Ankara, Turkey (Türkiye) (enrolling)
• Hacettepe University Medical School Nuclear Medicine Department — Ankara, Ankara, Turkey (Türkiye) (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.